Shots:
- NMPA approved limertinib (oral EGFRm TKI) to treat LA/M EGFR T790M-mutated NSCLC in adults, based P-IIb trial assessing limertinib in (n=301) NSCLC patients
- This study showed 68.8% ORR, 92.4% DCR, plus 11mos. mPFS with 11.1mos. mDoR. It also showed ORR & mPFS of 65.9% & 10.6mos., respectively in patients with assessable CNS lesions with favourable safety.
- Additionally, a P-III trial assessing limertinib vs gefitinib as 1L therapy of LA/M EGFRm+ NSCLC met its 1EP, results of which will be reported at upcoming conferences or publications. Another NDA for LA/M EGFR 19DEL+ or L858R+ NSCLC is under NMPA review
Ref: Innovent & Ask Biopharma | Image: Innovent & Ask Biopharma
Related News:- Innovent’s IBI343 Secures the NMPA’s Breakthrough Therapy Designation for Advanced Pancreatic Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
